Oral Ad5 Vector‐Based SARS‐CoV‐2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice
Journal of Medical Virology · 2025-02 · 97 (2)
DOI: 10.1002/jmv.70236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 13.02.2025. Verfasst von Tongyao Mao und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), NHC Key Laboratory for Medical Virology and Viral D…. Hauptthemen laut MEDLINE: Immunity, Mucosal, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: The research was supported by the National Key Research and Development Program of China (Finance Code 2022YFC2304302)..
Abstract (Originalsprache)
Mucosal immunity is essential for preventing viral infections through the mucosal route. The emerging SARS‐CoV‐2 variants have posed additional hurdles to the efficiency of existing vaccines. The rapid development of novel vaccines that generate broad mucosal and systemic immunity could be the most effective strategy to address this issue. In this study, we developed a recombinant and replication‐deficient type‐5 adenoviral vaccine with a built‐in double‐strand RNA adjuvant and the vaccine expresses the SARS‐CoV‐2 Omicron BA.1 spike (S) antigen (hereinafter referred to as “the oral vaccine”). We found that two doses of the oral vaccine in BALB/c mice generated long‐lasting S‐specific mucosal and systemic immune responses, as well as broad neutralizing antibodies and SIgA antibodies. In addition, we found that compared to an mRNA vaccine booster, using the oral vaccine as a booster could induce both effective mucosal and systemic immunity, addressing the limitation of mRNA vaccines in eliciting mucosal immunity. Prospective oral vaccines require further investigation into development and potential applications, particularly viral challenge experiments, before clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), NHC Key Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention,…
- School of Public Health, Gansu University of Chinese Medicine, Lanzhou, China.
ORCID-Profile: Tongyao Mao
Förderung
- The research was supported by the National Key Research and Development Program of China (Finance Code 2022YFC2304302).
Zitieren
APA
Mao, T., Zhang, P., Jiang, S., Li, D., Li, J., Zhang, Q., Wang, H., Kong, X., & Duan, Z. (2025). Oral Ad5 Vector‐Based SARS‐CoV‐2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70236
Vancouver
Mao T, Zhang P, Jiang S, Li D, Li J, Zhang Q, et al. Oral Ad5 Vector‐Based SARS‐CoV‐2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70236
BibTeX
@article{Mao2025,
author = {Mao, Tongyao and Zhang, Peng and Jiang, Surui and Li, Dandi and Li, Jinsong and Zhang, Qing and Wang, Hong and Kong, Xiangyu and Duan, Zhaojun},
title = {Oral Ad5 Vector‐Based SARS‐CoV‐2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice},
journal = {Journal of Medical Virology},
year = {2025},
volume = {97},
number = {2},
doi = {10.1002/jmv.70236}
}
EUVIMED